Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. - Wikidata - awgldk - TriplyDB

Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California.

Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California.

http://www.wikidata.org/entity/Q35170761

about

Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.Increased risk of thyroid diseases in patients with systemic lupus erythematosus: A nationwide population-based Study in Korea Cancer complicating systemic lupus erythematosus--a dichotomy emerging from a nested case-control study.Malignancy in systemic lupus erythematosus: what have we learned?A review of the application of inflammatory biomarkers in epidemiologic cancer research.Thyroid cancer in systemic lupus erythematosus: a meta analysis New classification criteria for systemic lupus erythematosus correlate with disease activity Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis.Incidence of neoplasms in the most prevalent autoimmune rheumatic diseases: a systematic review.Prostate cancer in systemic lupus erythematosus Systemic lupus erythematous and malignancy risk: a meta-analysis.Characteristics and prognosis of colorectal cancer associated with rheumatic disease.Mixed Connective Tissue Disease and Papillary Thyroid Cancer: A Case Report.Functional Module Analysis for Gene Coexpression Networks with Network Integration.Comparison of breast cancer risk in women with and without systemic lupus erythematosus in a Medicare population.Hierarchical modeling identifies novel lung cancer susceptibility variants in inflammation pathways among 10,140 cases and 11,012 controls.Standardised incidence ratios (SIRs) for cancer after renal transplant in systemic lupus erythematosus (SLE) and non-SLE recipients.AID dysregulation in lupus-prone MRL/Fas(lpr/lpr) mice increases class switch DNA recombination and promotes interchromosomal c-Myc/IgH loci translocations: modulation by HoxC4 Malignancies in systemic lupus erythematosus Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review.Malignancy as a comorbidity in rheumatic diseases.Immunosuppression and risk of cervical cancer.What is the background incidence of malignancy in children with rheumatic disease?Immunomodulation and lymphoma in humans.Bioreactivity of the crystalline silica polymorphs, quartz and cristobalite, and implications for occupational exposure limits (OELs).Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: evidence from a meta-analysis.A systematic review of the epidemiological literature on the risk of urological cancers in systemic lupus erythematosus.Incidence of cervical human papillomavirus infection in systemic lupus erythematosus women.Cervical neoplasia in systemic lupus erythematosus: a nationwide study.Breast cancer in systemic lupus.Systemic lupus erythematosus and malignancies risk.Dialogue: what can we learn about the relationship between systemic lupus erythematosus and haematological malignancies from linking disease registries?The most important questions in cancer research and clinical oncology-Question 2-5. Obesity-related cancers: more questions than answers Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus.Decreased breast cancer risk in systemic lupus erythematosus: the search for a genetic basis continues.High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort.Thyroid nodules in Hispanic patients with systemic lupus erythematosus.The age-risk relationship of haematologic malignancies in female patients with systemic lupus erythematosus: a nationwide retrospective cohort study.

P2860

Q26739361-F23969CF-D5A9-4478-BBF7-347503123F58 Q30580226-A68A4FB3-84B4-4B9C-83D3-9EBC74EE7C44 Q33842149-0C80FA0B-1B0D-4564-8BF9-EF0E655AA0C4 Q33937936-D096948E-6454-46CA-941D-A3177E03EB54 Q34087859-840C3F1F-6F74-4877-A8C4-9C314C799CC2 Q34135803-1784CF00-E0F9-44EB-852B-91B7D4DCC446 Q34371770-61E5F0B3-C2C3-458F-A205-029F7D1B66A4 Q34492782-EE2640BD-C150-4BC2-908C-F3D7593E3BB2 Q34637366-C35D4A72-EB1F-4ABF-96B5-3B67956D1194 Q35006892-059F4E89-6978-4ACF-A847-DD421FA9E724 Q35176767-6E37F2A5-6A5A-4807-A14D-F4C428D96527 Q35464068-34C060D4-2C70-4139-A611-C5F8D392C1C7 Q35464796-1A0665EB-F243-4ED6-AB2C-5989789CD73D Q35676140-7172D6CE-D107-41CB-9347-459A3D33E899 Q35934776-89D8C617-3006-4A33-BBD4-AD38D14154B8 Q36331261-9175FE44-9882-4BFE-8BB8-431E09577FB3 Q36416287-98E359C2-1590-4164-9E79-524B42B1B3CF Q36773349-22D9EA2B-6ECF-423B-BBD3-148963675B24 Q37007011-70CDC402-5B4A-4EBE-B1D7-5B97477D9FC7 Q37146254-DACF5C20-3A2F-48BA-9F37-C4B2D478C6D7 Q37433350-E2A12EF3-EA1B-4AB4-88E7-B8196260661C Q37808965-4B62C24E-EC9C-499E-8F74-4A3DBA6A64B1 Q38029322-83B0A8FF-FB41-4E3E-A797-0D89917C2F58 Q38069182-FB2B4128-84A2-43C1-9BD4-389A97EA1882 Q38078882-B9A1E0CC-0F9A-49D0-AB20-C9EF2FD9C626 Q38112841-D5A61B13-C9A7-497A-8EDE-29E613DBF95B Q38122211-6F97BDB2-802D-431D-BED7-AF3A5AE0ABD1 Q38178804-D1E52A71-2EA7-4CDD-AB46-2FCCD5CEA116 Q38187858-E83B7B19-B3C4-4D29-B631-CA8DF5DCC194 Q40383158-C52BCA00-D237-4E7C-A1AF-F25457947B79 Q40401221-6459EB46-A5A3-496D-ABB3-B49C2C6E651D Q40559886-DE868A84-71D2-42AB-8E62-DF7CC122D1C0 Q41441163-49C1BF92-94CA-4020-8BAA-EB653686A771 Q41976089-F865B0D5-9B47-4F4C-8A3A-4CCA83A6E862 Q42325041-E8927845-F415-4EB5-BB32-2DDAFCE4C7EB Q42652135-7EB2F87E-F7A2-4309-B5BF-5E715F6E5FE4 Q44212883-A63E25F9-EB77-4B7A-B7EC-201BCB94979A Q45362963-98921F27-A865-4BB7-A118-4CF994FB964D Q46164059-5BBE6204-5D4B-4EC0-83ED-F92845E454A5 Q50932896-3E0B3B6A-E2A9-41C2-9ACC-99BEA11C7AA3

P2860

Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California.

http://www.wikidata.org/entity/Q35170761

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Cancer risk in a cohort of pat ...... hematosus (SLE) in California.

@ast

Cancer risk in a cohort of pat ...... hematosus (SLE) in California.

@en

type

label

Cancer risk in a cohort of pat ...... hematosus (SLE) in California.

@ast

Cancer risk in a cohort of pat ...... hematosus (SLE) in California.

@en

prefLabel

Cancer risk in a cohort of pat ...... hematosus (SLE) in California.

@ast

Cancer risk in a cohort of pat ...... hematosus (SLE) in California.

@en

P1433

Q35170761-864FCF78-C1C9-4D8F-9531-A178A00336BE

P1476

Q35170761-6EEBFC56-B6AB-4AAE-8374-4F0E0C4AEB42

P2093

Q35170761-8DB2648C-C2EA-4672-BA19-091ED29048A9

Q35170761-E807E69F-FC57-49FC-BA2B-8BA40D2B8FA5

Q35170761-F7AB4A27-F131-4EA5-9BEC-EF52543A362A

Q35170761-FF8784A9-28DF-48F2-A06A-BF6C62479423

P2860

Q35170761-0450F2DA-220C-423A-98F2-34D4EE1624D6

Q35170761-07B08331-64CF-4706-B5B2-9308B5E2FE3F

Q35170761-07F21FD7-DB63-471B-ADC4-319D274309BD

Q35170761-0F0D39F0-2C68-4279-8DE5-7CB9C7CF9EC5

Q35170761-185BC87D-370F-4B90-99CE-6F61E7E74FC9

Q35170761-1BEE189E-9885-4A47-9108-A8B8EB638E5B

Q35170761-1F84E000-751B-4B15-992C-94E51B10323C

Q35170761-24275AD5-9A70-456B-8134-ED641A9E44A9

Q35170761-27B693E9-1BE9-4F6B-B789-60C591700D6E

Q35170761-29A6813D-F8F4-4EDF-B122-67480DF4BACE

P2888

Q35170761-CA0736C7-9E6A-4F43-A6F9-749E64FDBC92

P304

Q35170761-CF01D619-E531-460C-8A5B-5D6F0C79B0F5

P31

Q35170761-BC0D11CF-C19F-4EC2-9DF4-F5F27DE9CB23

P356

Q35170761-4E062161-59B7-4330-9990-F20DA8ED6941

P433

Q35170761-AEAB6C80-4C46-4BEC-A945-F5BC07E66B5D

P478

Q35170761-B9A2D180-EC9D-4AB6-A33B-404B29A876D6

P577

Q35170761-161D1DD6-E1D0-4547-B010-0634DDFAA13D

P698

Q35170761-B44A1CE4-3A78-44F6-9B9A-F3D2836A2E02

P921

Q35170761-7405A58F-FFD7-4D94-9DB4-9E792FCE8A4F

P932

Q35170761-DCB689E7-6FAE-42A0-8FDA-F29E00D045BE

P356

S10552-008-9151-8

P1433

Cancer Causes & Control

P1476

Cancer risk in a cohort of pat ...... hematosus (SLE) in California.

@en

P2093

Arti Parikh-Patel

http://www.w3.org/2001/XMLSchema#string

Mark Allen

http://www.w3.org/2001/XMLSchema#string

Richard H White

http://www.w3.org/2001/XMLSchema#string

Rosemary Cress

http://www.w3.org/2001/XMLSchema#string

P2860

Bladder cancer after cyclophosphamide therapy for lupus nephritis

Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis

Cyclophosphamide treatment of systemic lupus erythematosus: risk of bladder cancer exceeds benefit

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Statistical methods in cancer research. Volume II--The design and analysis of cohort studies

Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy.

Increased risk of cancer in patients with systemic lupus erythematosus.

Environmental factors predicting nephritis in systemic lupus erythematosus

How to improve morbidity and mortality in systemic lupus erythematosus.

Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review.

P2888

s10552-008-9151-8

P304

887-894

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10552-008-9151-8

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18386139

http://www.w3.org/2001/XMLSchema#string

P921

P932

4357418

http://www.w3.org/2001/XMLSchema#string